Canine Liver Transplantation Under Nva2-cyclosporine Versus Cyclosporine

Overview

Journal Transplantation

Specialty General Surgery

Date 1986 Mar 1

PMID 3513388

Citations 9

Authors

S Todo

K A Porter

I Kam

S Lynch

R Venkataramanan

A Dewolf

T E Starzl

Affiliations

Soon will be listed here.

Abstract

The immunosuppressive qualities and other features of a new cyclosporine (CsA) analogue, Nva2-cyclosporine (Nva2-CsA) were examined using canine orthotopic liver allografts. The mean survival time was 11.8 +/- 9.6 (SD) days in dogs without treatment, 60.8 +/- 4.4 days with Nva2-CsA and 65.1 +/- 33.0 days with CsA. Functional abnormalities indicating toxic side effects were not noted either with Nva2-CsA or with CsA. Using the same oral dose, the rate of blood level rise and the amount of the rise were greater with Nva2-CsA. Histopathologically, Nva2-CsA treatment was associated with the same degree of hydropic vocuolation in the pars recta of the proximal tubules as CsA treatment. Thus, in the dog, Nva2-CsA had identical immunosuppressive properties as CsA, with no functionally detectable toxicity affecting the liver and kidney.

Citing Articles

Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.

Diehl R, Ferrara F, Muller C, Dreyer A, McLeod D, Fricke S Cell Mol Immunol. 2016; 14(2):146-179.

PMID: 27721455 PMC: 5301156. DOI: 10.1038/cmi.2016.39.

IMMUNOSUPPRESSION WITH FR 900506 FOR CANINE KIDNEY AND LIVER TRANSPLANTATION.

Todo S, Makowka L, Starzl T Surg Res Commun. 2011; 1:333-340.

PMID: 21552393 PMC: 3089006.

Cyclosporine G Analysis and Monitoring by High-Pressure Liquid Chromatography.

Zaghloul I, Burckart G, Starzl T, Todo S, Ptachcinski R, Venkataramanan R Transplant Proc. 2010; 18(4):771-773.

PMID: 20852736 PMC: 2940318.

Animal research in liver transplantation with special reference to the dog.

Todo S, Kam I, Lynch S, Starzl T Semin Liver Dis. 1985; 5(4):309-17.

PMID: 3909422 PMC: 2955295. DOI: 10.1055/s-2008-1040626.

Comparative pharmacokinetics of cyclosporine and NVa2-cyclosporine in dogs.

Venkataramanan R, Todo S, Zaghloul I, Lynch S, Kam I, Ptachcinski R Transplant Proc. 1987; 19(1 Pt 2):1265-6.

PMID: 3274314 PMC: 2911137.

References

Starzl T, Weil 3rd R, Iwatsuki S, Klintmalm G, Schroter G, Koep L . The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet. 1980; 151(1):17-26. PMC: 2727074. View

Kam I, Lynch S, Todo S, Dewolf A, McSteen F, Jakab F . Low flow venovenous bypasses in small dogs and pediatric patients undergoing replacement of the liver. Surg Gynecol Obstet. 1986; 163(1):33-6. PMC: 2677019. View

Calne R, Rolles K, White D, Thiru S, Evans D, McMaster P . Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979; 2(8151):1033-6. DOI: 10.1016/s0140-6736(79)92440-1. View

Ryffel B, Siegl H, Petric R, Muller A, Hauser R, Mihatsch M . Nephrotoxicity of cyclosporine in spontaneously hypertensive rats: effects on blood pressure and vascular lesions. Clin Nephrol. 1986; 25 Suppl 1:S193-8. View

STARLZ T, KAUPP Jr H, BROCK D, LAZARUS R, Johnson R . Reconstructive problems in canine liver homotransplantation with special reference to the postoperative role of hepatic venous flow. Surg Gynecol Obstet. 1960; 111:733-43. PMC: 2729187. View